Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience.

Abstract

The present study reports the Spanish PETHEMA group experience in 31 heavily pretreated relapsed/refractory acute lymphoblastic leukemia (ALL) and lymphoma (LL) patients treated with clofarabine-based regimens. The complete remission (CR) rate was 31% (median CR duration of 3 months [range 2–28]) and the overall survival probability at 1 year was 10% (95%CI 4–16%). Responses were seen in B and T lineage diseases and in patients with adverse cytogenetics. Hematological and infectious grade >3 toxicities were found in 100 and 67% of the patients, respectively, with 7 (23%) treatment-related deaths. Other organ toxicities were infrequent. Clofarabine-based chemotherapy regimens might induce CRs in ALL and LL patients, but hematological toxicity and infections may limit their use in heavily pretreated patients.

• Authors: Pere Barba, Antonia Sampol, María Calbacho, José Gonzalez, Josefina Serrano, Pilar Martínez-Sánchez, Pascual Fernández, Raimundo García-Boyero, Javier Bueno, Josep Maria Ribera
• Journal: American journal of hematology (Am J Hematol) Vol. 87 Issue 6 Pg. 631-4 (Jun 2012) ISSN: 1096-8652 [Electronic] United States
• PMID: 22431002 (Publication Type: Letter, Multicenter Study)

Chemical References

• Adenine Nucleotides
• Antimetabolites, Antineoplastic
• Arabinonucleosides
• Cytarabine
• Etoposide
• Clofarabine
• Cyclophosphamide

Topics

• Adenine Nucleotides (administration & dosage, adverse effects, therapeutic use)
• Adolescent
• Adult
• Aged
• Antimetabolites, Antineoplastic (administration & dosage, adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Arabinonucleosides (administration & dosage, adverse effects, therapeutic use)
• Clofarabine
• Cyclophosphamide (administration & dosage)
• Cytarabine (administration & dosage)
• Drug Evaluation
• Etoposide (administration & dosage)
• Female
• Humans
• Male
• Middle Aged
• Off-Label Use
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)
• Retrospective Studies
• Salvage Therapy
• Spain
• Young Adult